Flaraxin is effective in 90% of oncologic diseases
FLARAXIN is a preparation of vegetarian origin, a non-toxic anti-tumoral phytopreparation, interferonogene, stimulating tumoral necrosis factor,destroys tumoral tissue. Immunomodulator and antioxidant. Prevents metastatic spreading and relapse.
Scientific & treatment center for cancer curing Phoenix developed and clinically tested a number of biologically active preparations of plant origin. For the first time, has been used a unique technology of plant concentrates, allowing several times to increase the biological activity of number natural substances.
As a result of comprehensive research has developed a number of medical treatments for cancer patients by the FLARAXIN together with a number of biologically active preparations.
FLARAXIN
is a non-toxic anti-tumoral phytopreparation, interferonogene, stimulating tumoral necrosis factor,destroys tumoral tissue. Immunomodulator and antioxidant. Prevents metastatic spreading and relapse.
The history of Flaraxin: According to the data of the preparation clinical trial it was established that “Flaraxin” is a remedy of vegetable origin, active components of which are vegetable polyphenoles. During the trial it was found out that “Flaraxin” has the ability to stimulate the secretion of endogenic interferon and the neoplasm necrosis factor, promotes immunologic background normalization and smoothes out the correlation of immunocomponent cells CD4/CD8 (helpers-suppressors) and increases the number of natural killers (NKcells).
During the immune-biochemical trial the ability of “Flaraxin” to connect with oncophetal proteins, causing their micro-denaturation damages was established. Cancerostatic effect was explicated by “Flaraxin” influence on metabolism of neoplasm cells, causing their death.
Clinical trial of the preparation “Flaraxin” was carried out on the basis of oncology department of Kiev medical institute in the period from September 1990 to January 1991 and in Kiev Oncology SRI under oncologic process in the stage of neglect desolation in patients with melanoblastoma in the period from December 1992 to October 1993
FLARAXIN should be recommended to the wide clinical application as a cytostatics drug, which proved to be effective in patients with cancer of the following organs: cerebrum (brain) cancer, melanoma, melanoblastoma, breast cancer, mammary gland cancer, lungs cancer, stomach cancer, bladder cancer, colorectal cancer, colon cancer, uterus cancer, cervix cancer, ovaries cancer, neck of womb and womb cancer, bowels cancer, prostate gland, adenoma, mediastinal cancer, non-malignant neoplasm, improving general state of patients, not suppressing hemopoiesis and does not have an adverse effect on CNS, does not disrupt the function of the vitally important organs (liver, kidneys, cardiovascular system (CVS)) , with very rare exception of side effects.
FLARAXIN can be administered not only to advanced cancer patients, but also for curable patients in combination with the radiological, and in combination with chemo-regimens and surgery (as prevention of cancer recurrence).
The clinical administration of drug FLARAXIN is recommended by us in the following cases:
The largest benefit from FLARAXIN is achieved in patients with the pretumorous proliferating processes, and also in the persons, with the minimum tumor process, after the radical surgical treatment, when it is necessary to conduct the restoration of the anti-tumor resistance of organism and its homeostatic mechanisms;
The history of Flaraxin: According to the data of the preparation clinical trial it was established that “Flaraxin” is a remedy of vegetable origin, active components of which are vegetable polyphenoles. During the trial it was found out that “Flaraxin” has the ability to stimulate the secretion of endogenic interferon and the neoplasm necrosis factor, promotes immunologic background normalization and smoothes out the correlation of immunocomponent cells CD4/CD8 (helpers-suppressors) and increases the number of natural killers (NKcells).
During the immune-biochemical trial the ability of “Flaraxin” to connect with oncophetal proteins, causing their micro-denaturation damages was established. Cancerostatic effect was explicated by “Flaraxin” influence on metabolism of neoplasm cells, causing their death.
Clinical trial of the preparation “Flaraxin” was carried out on the basis of oncology department of Kiev medical institute in the period from September 1990 to January 1991 and in Kiev Oncology SRI under oncologic process in the stage of neglect desolation in patients with melanoblastoma in the period from December 1992 to October 1993
FLARAXIN should be recommended to the wide clinical application as a cytostatics drug, which proved to be effective in patients with cancer of the following organs: cerebrum (brain) cancer, melanoma, melanoblastoma, breast cancer, mammary gland cancer, lungs cancer, stomach cancer, bladder cancer, colorectal cancer, colon cancer, uterus cancer, cervix cancer, ovaries cancer, neck of womb and womb cancer, bowels cancer, prostate gland, adenoma, mediastinal cancer, non-malignant neoplasm, improving general state of patients, not suppressing hemopoiesis and does not have an adverse effect on CNS, does not disrupt the function of the vitally important organs (liver, kidneys, cardiovascular system (CVS)) , with very rare exception of side effects.
FLARAXIN can be administered not only to advanced cancer patients, but also for curable patients in combination with the radiological, and in combination with chemo-regimens and surgery (as prevention of cancer recurrence).
The clinical administration of drug FLARAXIN is recommended by us in the following cases:
The largest benefit from FLARAXIN is achieved in patients with the pretumorous proliferating processes, and also in the persons, with the minimum tumor process, after the radical surgical treatment, when it is necessary to conduct the restoration of the anti-tumor resistance of organism and its homeostatic mechanisms;
FLARAXIN combined together with poly-Chemotherapy proved to be highly effective among the patients with heavy cancer process due to its specific anti-cancerous action and protective properties. Treatment with Flaraxin can be done in mono and complex therapy; moreover FLARAXIN can be administered before Poly-Chemotherapy, in periods between treatment cycles of Chemotherapy, and for stabilization after positive results achieved by standard therapy due to its minimum toxicity and ability to stop metastatic spreading. Flaraxin exists in intravenous injections, capsules, tablets for oral and cones (suppository) for rectal and vaginal application.
FLARAXIN is compatible with many anti-cancer drugs according to it’s chemical properties, with exception of those that contain iron (Fe) inside, because Flaraxin can form a complexes with iron (Fe).
FLARAXIN is effective with the following diseases: brain cancer, melanoma, melanoblastoma, breast cancer, lung cancer, mammary gland cancer, uterus cancer, cervix cancer, ovaries cancer, bowels cancer, neck of womb cancer, womb cancer, prostate gland cancer, adenoma, mediastinal cancer, colorectal cancer, colon cancer, stomach cancer, bladder cancer, non-malignant neoplasm, which are equivalent to 90% of a total quantity of oncological diseases. FLARAXIN is most effective in the cases of the small tumors, when vital organs (liver, kidneys) are partly defeated. In these cases the complete reduction of tumor can be reached.
FLARAXIN is compatible with many anti-cancer drugs according to it’s chemical properties, with exception of those that contain iron (Fe) inside, because Flaraxin can form a complexes with iron (Fe).
FLARAXIN is effective with the following diseases: brain cancer, melanoma, melanoblastoma, breast cancer, lung cancer, mammary gland cancer, uterus cancer, cervix cancer, ovaries cancer, bowels cancer, neck of womb cancer, womb cancer, prostate gland cancer, adenoma, mediastinal cancer, colorectal cancer, colon cancer, stomach cancer, bladder cancer, non-malignant neoplasm, which are equivalent to 90% of a total quantity of oncological diseases. FLARAXIN is most effective in the cases of the small tumors, when vital organs (liver, kidneys) are partly defeated. In these cases the complete reduction of tumor can be reached.
Stccc Phoenix is looking for doctors and medical centers around the world to work together ,to bring cancer into absolute remission ?
You can contact us: Contact information
SCIENTIFIC & TREATMENT CENTER FOR CANCER CURING PHOENIX
(License of the Ukrainian Ministry of Health Seria АБ №299302)
Contact adres: Svobody sq. 7, office 378, 61022-Kharkiv, Ukraine
Tel: +38 (067) 571 77 64 E-mail : stccc.phoenix.ua@gmail.com